Epitopea
Transatlantic cancer immunotherapeutics company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $31.0m | Series A | |
| Total Funding | 000k | ||
| GBP | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 474 % |
| EBITDA | 0000 | 0000 |
| % EBITDA margin | (3342 %) | (928 %) |
| Profit | 0000 | 0000 |
| % profit margin | (3035 %) | (873 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Epitopea is a transatlantic cancer immunotherapeutics company with operations in Cambridge, UK, and Montreal, Canada, established in 2021. The company is focused on developing immunotherapies to treat cancer by targeting a novel class of tumor-specific antigens (TSAs) known as Cryptigen™ antigens.
These antigens are broadly shared among patients with the same type of cancer. Epitopea leverages a proprietary platform to identify these markers on the surface of cancer cells. The company is developing a pipeline of accessible, off-the-shelf RNA-based immunotherapies. This approach aims to provide broadly applicable cancer treatments.
Epitopea has entered into a license and research collaboration agreement with MSD (Merck) to identify Cryptigen™ tumor-specific antigens. The company has secured over $45 million in financing to support the strategic development and clinical entry of its lead product candidate, Cryptigen™.
Keywords: cancer immunotherapeutics, RNA-based immunotherapies, tumor-specific antigens, Cryptigen, oncology, biotechnology, clinical development, off-the-shelf therapies, transatlantic, cancer treatment